NASDAQ:DCTH Delcath Systems (DCTH) Stock Forecast, Price & News $4.05 -0.06 (-1.46%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$4.03▼$4.3450-Day Range$3.12▼$5.7552-Week Range$2.34▼$7.99Volume240,887 shsAverage Volume373,769 shsMarket Capitalization$61.87 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Delcath Systems MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside344.4% Upside$18.00 Price TargetShort InterestHealthy4.88% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.28Based on 3 Articles This WeekInsider TradingAcquiring Shares$50,640 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.13) to ($1.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.74 out of 5 starsMedical Sector86th out of 972 stocksSurgical & Medical Instruments Industry12th out of 98 stocks 3.5 Analyst's Opinion Consensus RatingDelcath Systems has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.00, Delcath Systems has a forecasted upside of 344.4% from its current price of $4.05.Amount of Analyst CoverageDelcath Systems has only been the subject of 4 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.88% of the outstanding shares of Delcath Systems have been sold short.Short Interest Ratio / Days to CoverDelcath Systems has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Delcath Systems has recently decreased by 22.22%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDelcath Systems does not currently pay a dividend.Dividend GrowthDelcath Systems does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DCTH. Previous Next 2.9 News and Social Media Coverage News SentimentDelcath Systems has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Delcath Systems this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for DCTH on MarketBeat in the last 30 days. This is a decrease of -81% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Delcath Systems to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Delcath Systems insiders have bought more of their company's stock than they have sold. Specifically, they have bought $50,640.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders21.10% of the stock of Delcath Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions85.15% of the stock of Delcath Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Delcath Systems are expected to grow in the coming year, from ($2.13) to ($1.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Delcath Systems is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Delcath Systems is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Delcath Systems (NASDAQ:DCTH) StockDelcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Read More DCTH Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DCTH Stock News HeadlinesSeptember 30, 2023 | americanbankingnews.comShort Interest in Delcath Systems, Inc. (NASDAQ:DCTH) Decreases By 22.2%September 14, 2023 | finance.yahoo.comThese 2 “Strong Buy” Penny Stocks Could Soar to $17 (Or Higher), Say AnalystsOctober 1, 2023 | Legacy Research (Ad)Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”September 11, 2023 | finance.yahoo.comA Retrospective Comparative Study of Chemosat and SIRT Presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual MeetingSeptember 7, 2023 | nasdaq.comCanaccord Genuity Maintains Delcath Systems (DCTH) Buy RecommendationSeptember 7, 2023 | markets.businessinsider.comWhere Delcath Systems Stands With AnalystsSeptember 5, 2023 | finance.yahoo.comDelcath Systems to Participate at the H.C. Wainwright 25th Annual Investor Conference on September 12 and 13, 2023September 1, 2023 | finance.yahoo.comDelcath Systems, Inc. Announces Additional $35 Million in Funding Tied to the FDA Approval of HEPZATO KIT™October 1, 2023 | Legacy Research (Ad)Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”August 31, 2023 | msn.comDelcath Systems (DCTH) Price Target Increased by 10.98% to 18.56August 29, 2023 | finance.yahoo.comDelcath Systems Announces an Independent Investigator Presentation at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual MeetingAugust 25, 2023 | finance.yahoo.comInsider Buys Additional US$51k In Delcath Systems StockAugust 16, 2023 | msn.comRoth MKM Maintains Delcath Systems (DCTH) Buy RecommendationAugust 16, 2023 | msn.comBTIG Maintains Delcath Systems (DCTH) Buy RecommendationAugust 16, 2023 | markets.businessinsider.comAnalyst Expectations for Delcath Systems's FutureAugust 16, 2023 | msn.comDelcath Systems: Prepare For Substantial Dilution Post-FDA Approval For The Hepzato KitAugust 15, 2023 | benzinga.comThinking about buying stock in Nikola, Delcath Systems, Taysha Gene Therapies, Tempest Therapeutics, or AGBA Group Holding?August 15, 2023 | msn.comHC Wainwright & Co. Maintains Delcath Systems (DCTH) Buy RecommendationAugust 15, 2023 | benzinga.comDelcath Systems Stock Is Rocketing Higher: What's Going On?August 15, 2023 | msn.comDelcath Systems Stock Soars 90% In One Session - Here's WhyAugust 15, 2023 | msn.comTuesday’s Wall Street Highlights: Delcath Systems, Getty Images, Home Depot, Berkshire Hathaway, and moreAugust 15, 2023 | marketwatch.comDelcath Systems Shares Soar Premarket on FDA Nod for Hepzato Kit >DCTHAugust 15, 2023 | markets.businessinsider.comWhy Is Delcath Systems (DCTH) Stock Up 72% Today?August 14, 2023 | markets.businessinsider.comDelcath Systems : FDA Approves HEPZATO KIT To Treat Metastatic Uveal Melanoma In AdultsAugust 14, 2023 | finance.yahoo.comDelcath Systems, Inc. Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal MelanomaAugust 12, 2023 | finance.yahoo.comDelcath Systems, Inc.'s (NASDAQ:DCTH) Path To ProfitabilityAugust 10, 2023 | finanznachrichten.deDelcath Systems, Inc.: Delcath Systems Reports Second Quarter 2023 Results and Provides Business UpdateSee More Headlines Receive DCTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter. Email Address DCTH Company Calendar Last Earnings8/09/2023Today9/30/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DCTH CUSIPN/A CIK872912 Webdelcath.com Phone212-489-2100Fax212-489-2102Employees52Year FoundedN/APrice Target and Rating Average Stock Price Forecast$18.00 High Stock Price Forecast$21.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+344.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,510,000.00 Net Margins-1,258.21% Pretax Margin-1,272.32% Return on EquityN/A Return on Assets-147.89% Debt Debt-to-Equity RatioN/A Current Ratio1.75 Quick Ratio1.53 Sales & Book Value Annual Sales$2.64 million Price / Sales23.46 Cash FlowN/A Price / Cash FlowN/A Book Value($0.58) per share Price / Book-6.98Miscellaneous Outstanding Shares15,276,000Free Float12,053,000Market Cap$61.87 million OptionableNot Optionable Beta0.75 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Gerard J. Michel MBA (Age 60)MS, CEO & Director Comp: $671.6kMr. John Purpura M.S. (Age 62)Chief Operating Officer Comp: $485.92kDr. Johnny John M.D. (Age 59)Sr. VP Clinical Devel. & Medical Affairs Comp: $472.16kMs. Sandra Pennell (Age 43)Sr. VP of Fin. and Principal Financial & Accounting Officer Mr. David HoffmanGen. Counsel, Corp. Sec. & Chief Compliance OfficerDr. Vojislav Vukovic M.D. (Age 56)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsLucid DiagnosticsNASDAQ:LUCDBrainsWayNASDAQ:BWAYT2 BiosystemsNASDAQ:TTOOPro-DexNASDAQ:PDEXInspireMDNYSE:NSPRView All CompetitorsInsiders & InstitutionsJohn Richard SylvesterBought 10,550 shares on 8/21/2023Total: $50,640.00 ($4.80/share)Stonepine Capital Management LLCBought 378,787 shares on 8/16/2023Ownership: 3.567%BVF Inc. ILBought 1,178,787 shares on 8/15/2023Ownership: 11.100%Citadel Advisors LLCBought 18,373 shares on 8/15/2023Ownership: 0.173%Cibc World Market Inc.Bought 21,885 shares on 8/11/2023Ownership: 1.174%View All Insider TransactionsView All Institutional Transactions DCTH Stock - Frequently Asked Questions Should I buy or sell Delcath Systems stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Delcath Systems in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DCTH shares. View DCTH analyst ratings or view top-rated stocks. What is Delcath Systems' stock price forecast for 2023? 4 Wall Street analysts have issued 1-year price targets for Delcath Systems' stock. Their DCTH share price forecasts range from $13.00 to $21.00. On average, they predict the company's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 344.4% from the stock's current price. View analysts price targets for DCTH or view top-rated stocks among Wall Street analysts. How have DCTH shares performed in 2023? Delcath Systems' stock was trading at $3.60 at the beginning of the year. Since then, DCTH shares have increased by 12.5% and is now trading at $4.05. View the best growth stocks for 2023 here. Are investors shorting Delcath Systems? Delcath Systems saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 744,900 shares, a decline of 22.2% from the August 31st total of 957,700 shares. Based on an average trading volume of 2,190,000 shares, the days-to-cover ratio is currently 0.3 days. View Delcath Systems' Short Interest. When is Delcath Systems' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our DCTH earnings forecast. How were Delcath Systems' earnings last quarter? Delcath Systems, Inc. (NASDAQ:DCTH) released its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.09. The firm had revenue of $0.50 million for the quarter, compared to the consensus estimate of $0.73 million. When did Delcath Systems' stock split? Delcath Systems's stock reverse split on the morning of Tuesday, October 22nd 2019. The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What is Delcath Systems' stock symbol? Delcath Systems trades on the NASDAQ under the ticker symbol "DCTH." How do I buy shares of Delcath Systems? Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Delcath Systems' stock price today? One share of DCTH stock can currently be purchased for approximately $4.05. How much money does Delcath Systems make? Delcath Systems (NASDAQ:DCTH) has a market capitalization of $61.87 million and generates $2.64 million in revenue each year. The company earns $-36,510,000.00 in net income (profit) each year or ($3.13) on an earnings per share basis. How can I contact Delcath Systems? Delcath Systems' mailing address is 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019. The official website for the company is delcath.com. The company can be reached via phone at 212-489-2100, via email at investorrelations@delcath.com, or via fax at 212-489-2102. This page (NASDAQ:DCTH) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Delcath Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.